Neuro & ImmuneRA10
Single or box
Loading product
Loading product
Neuro & Immune · Research material
Package information
For product inquiries and additional information, contact lonestarpeptideco@gmail.com.
Compliance notice: For laboratory research use only. Not for human or veterinary use.
Product information is intended for laboratory, academic and commercial researchers aged 18 or over.
Material profile
A standardised low-molecular-weight peptide preparation obtained by controlled enzymatic breakdown of purified porcine brain protein, supplied as a defined-fraction mixture rather than a single molecular entity. Supplied as a lyophilized powder at 60 mg in one vial. A box of 10 is available as an optional package. It is catalogued as a research-grade reference peptide for receptor-binding, electrophysiology and analytical method work. For laboratory research use only. Not for human or veterinary use.
Catalog record
| Product | Cerebrolysin — 60 mg |
|---|---|
| Catalog SKU | CBL60 |
| Compound | Cerebrolysin |
| Appearance | Clear to faintly amber solution concentrate |
| Fill per vial | 60 mg |
| Storage condition | -20 °C, desiccated, protect from light |
Laboratory handling
Arrives as a sealed lyophilized vial inside an insulated cold-shipped carton. Store at -20 degrees C, desiccated and protected from light; short-chain peptides of this type degrade fastest under combined humidity and UV exposure. Open, aliquot and dispose of the material strictly according to the receiving laboratory's own protocols.
Evidence first
This listing does not currently publish lot-specific analytical results. Request and review the applicable documentation before using the material in laboratory work.
Published literature
Cerebrolysin is a proprietary peptide preparation derived from purified porcine brain tissue, containing low-molecular-weight peptide fragments and free amino acids designed to mimic fragments of endogenous neurotrophic factors such as BDNF, NGF, and GDNF. In rat transient middle-cerebral-artery-occlusion (ischemia) models, published studies examined its association with infarct volume, neuroinflammatory gene expression, and the CREB/PGC-1a signaling pathway. Separate rodent work examined Keap1/Nrf2 antioxidant-pathway markers in a forebrain ischemic-reperfusion model, and a transgenic mouse model of Alzheimer's-type pathology examined behavioral and neuropathological markers following chronic administration. Cerebrolysin has not completed human clinical trials and holds no regulatory approval for any use.
Describes what the cited studies examined in the systems noted above — not a claim about outcomes for people. Not medical advice.
Product support
No downloadable certificate is currently attached to this listing. Email lonestarpeptideco@gmail.com if your laboratory requires lot-specific documentation for review.
Use the package selector to review the single-vial and box-of-10 formats, then use Email to inquire if you want to ask about that product.
The catalog storage condition is -20 °C, desiccated, protect from light. Follow the handling information on this page and your laboratory's written procedures.
No. It is presented only as laboratory research material and is not for human or veterinary use, food, drugs, cosmetics, household use, or self-administration.
Catalog navigation
Other catalog records grouped under the same editorial collection.
Product inquiries
Contact Lone Star Peptide Co. for product information and inquiries.
Email to inquireRequired notice
For laboratory research use only. Not for human or veterinary use, food, drugs, cosmetics, household use, or self-administration. Product information is provided for material identification, handling, and analytical documentation; it is not medical advice or a statement of clinical safety or effectiveness.